Search results
Low stress resilience is linked to increased risk of psoriasis
Medical Xpress· 4 days agoAs part of the enlistment process, all the men underwent psychological assessment in accordance with...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 4 days agoTakeaway Humira was one of the first biologic medications approved for psoriatic arthritis in 2005...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 5 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 2 days agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 5 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior...
Research shows linked biological pathways driving skin inflammation
Medical Xpress· 5 days agoLed by researchers at NYU Langone Health, the new study found that the interleukin-17 (IL-17)...
Maintenance Tx With Guselkumab for UC Meets All Endpoints
Medscape· 4 days agoGuselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
ETF DAILY NEWS· 6 days agoPanagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure ...
AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program
FierceBiotech· 4 days agoAltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...
Johnson & Johnson (NYSE:JNJ) Trading Down 1.1%
ETF DAILY NEWS· 14 hours agoShares of Johnson & Johnson (NYSE:JNJ – Get Free Report) were down 1.1% during mid-day trading on Thursday . The company traded as low as $151.70 and last traded at $151.81. Approximately 1,428,737 ...
